PanTHERA’s breakthrough lies in a novel class of molecules called ice recrystallization inhibitors (IRIs). These synthetic compounds control the size and formation of ice crystals during freezing and thawing, dramatically improving the survival and functionality of preserved cells, tissues, and organs. This leap forward addresses one of the biggest challenges in cryopreservation—and opens new doors for fields ranging from cell and gene therapy to organ transplantation and reproductive medicine.
A strategic move that combines innovation and impact
With this acquisition, BioLife Solutions—a leader in bioproduction tools and services—is strengthening its position as a pure-play bioproduction consumables company. For PanTHERA, the deal represents the culmination of years of scientific innovation and strategic collaboration.
PanTHERA was co-founded by Dr. Robert Ben, a full professor in the Department of Chemistry and Biomolecular Sciences at the University of Ottawa, and Dr. Jason Acker from the University of Alberta. Their work has brought forward a class of cryoprotectants that go beyond simply freezing biological material—they actively protect it from the damage caused by ice.
“We’re excited to see this tech scale globally with BioLife’s leadership—it aligns perfectly with Canada’s vision for research commercialization and innovation.”
Robert Ben
— Professor, Department of Chemistry and Biomolecular Sciences
Support from University of Ottawa nurtures innovation
The story of PanTHERA CryoSolutions is also a powerful testament to the role of academic institutions in driving innovation with real-world applications. The University of Ottawa was instrumental in the early development of the company by providing laboratory space for manufacturing which PanTHERA subsequently modified for GMP production of the ice recrystallization inhibitors. In addition, uOttawa has provided access to key infrastructure.
“From the start, the University of Ottawa supported our mission to commercialize the ice recrystallization inhibitor (IRI) technology that had the potential to dramatically change how we approach cryopreservation” added Dr. Ben.
"Our partnership with PanTHERA CryoSolutions established a responsive support model that evolved with their needs while building our own capacity to assist diverse startups. This collaboration sparked our graduate student entrepreneurship programs, positioning the Faculty of Science as a campus leader in research and commercialization. PanTHERA's success demonstrates how targeted institutional support transforms scientific breakthroughs into market solutions while fostering a sustainable innovation ecosystem" explained former Vice-Dean of Innovation, Entrepreneurship and Strategic Partnerships, and current Vice-Dean Research at the Faculty of Science, Alexandre Poulain.
Building toward a cryo-optimized future
The acquisition follows a strategic partnership formed in 2020, when BioLife Solutions and Casdin Capital invested $2 million USD into PanTHERA to accelerate development of IRIs for clinical and commercial use. That partnership laid the foundation for today’s announcement and underscores a shared belief in the global impact of cryopreservation innovation.
As PanTHERA’s technology integrates into BioLife’s broader offerings, researchers and clinicians around the world will gain access to better tools—ones that safeguard the integrity of their work, and ultimately, the health of their patients.